IntoCell, Inc. (KOSDAQ:287840)
South Korea · Delayed Price · Currency is KRW 24,400
+900 (3.83%)
At close: Aug 4, 2025, 3:30 PM KST
Sage Therapeutics Income Statement
Financials in millions KRW. Fiscal year is January - December.
Millions KRW. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | 2019 - 2020 |
|---|---|---|---|---|---|---|---|
Period Ending | Mar '25 Mar 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 | 2019 - 2020 |
| 2,948 | 2,905 | 1,616 | - | 140.03 | - | Upgrade | |
Revenue Growth (YoY) | 176.59% | 79.72% | - | - | - | - | Upgrade |
Cost of Revenue | 17.32 | 13.59 | 5.4 | 4.92 | 4.17 | 6.31 | Upgrade |
Gross Profit | 2,930 | 2,891 | 1,611 | -4.92 | 135.86 | -6.31 | Upgrade |
Selling, General & Admin | 1,701 | 1,573 | 1,464 | 1,749 | 1,683 | 1,045 | Upgrade |
Research & Development | 9,775 | 10,816 | 17,198 | 7,354 | 3,182 | 3,349 | Upgrade |
Other Operating Expenses | 27.25 | 26.79 | 46.22 | 12.12 | 12.02 | 19.55 | Upgrade |
Operating Expenses | 11,756 | 12,682 | 19,001 | 9,456 | 5,214 | 4,615 | Upgrade |
Operating Income | -8,826 | -9,790 | -17,390 | -9,461 | -5,078 | -4,622 | Upgrade |
Interest Expense | -295.75 | -314.74 | -61.08 | -3.07 | -675.48 | -1,546 | Upgrade |
Interest & Investment Income | 579.84 | 574.83 | 672.57 | 805.39 | 433.63 | 105.33 | Upgrade |
Currency Exchange Gain (Loss) | -387.97 | -399.88 | -56.85 | -22.76 | 2.5 | -9.74 | Upgrade |
Other Non Operating Income (Expenses) | -4.5 | 4.29 | 27.68 | 32.18 | -2,026 | -3,718 | Upgrade |
EBT Excluding Unusual Items | -8,935 | -9,926 | -16,807 | -8,649 | -7,343 | -9,789 | Upgrade |
Gain (Loss) on Sale of Investments | -15.32 | 12.84 | 63.46 | -17.33 | 11.67 | - | Upgrade |
Asset Writedown | - | - | -31.58 | - | - | - | Upgrade |
Pretax Income | -8,950 | -9,913 | -16,775 | -8,667 | -7,331 | -9,789 | Upgrade |
Net Income | -8,950 | -9,913 | -16,775 | -8,667 | -7,331 | -9,789 | Upgrade |
Net Income to Common | -8,950 | -9,913 | -16,775 | -8,667 | -7,331 | -9,789 | Upgrade |
Shares Outstanding (Basic) | 13 | 13 | 13 | 13 | 11 | 6 | Upgrade |
Shares Outstanding (Diluted) | 13 | 13 | 13 | 13 | 11 | 6 | Upgrade |
Shares Change (YoY) | 1.47% | 1.07% | -0.00% | 15.73% | 86.09% | 6.35% | Upgrade |
EPS (Basic) | -679.25 | -756.00 | -1293.00 | -668.00 | -654.00 | -1625.00 | Upgrade |
EPS (Diluted) | -679.25 | -756.00 | -1293.00 | -668.00 | -654.00 | -1625.00 | Upgrade |
Free Cash Flow | -7,291 | -7,117 | -17,007 | -6,436 | -4,168 | -5,072 | Upgrade |
Free Cash Flow Per Share | -553.37 | -542.77 | -1310.88 | -496.10 | -371.79 | -842.03 | Upgrade |
Gross Margin | 99.41% | 99.53% | 99.67% | - | 97.02% | - | Upgrade |
Operating Margin | -299.44% | -337.01% | -1075.82% | - | -3626.12% | - | Upgrade |
Profit Margin | -303.64% | -341.23% | -1037.82% | - | -5235.49% | - | Upgrade |
Free Cash Flow Margin | -247.37% | -244.99% | -1052.17% | - | -2976.28% | - | Upgrade |
EBITDA | -8,158 | -9,105 | -16,547 | -8,685 | -4,432 | -4,060 | Upgrade |
D&A For EBITDA | 667.74 | 684.79 | 842.83 | 776.07 | 646.08 | 561.51 | Upgrade |
EBIT | -8,826 | -9,790 | -17,390 | -9,461 | -5,078 | -4,622 | Upgrade |
Source: S&P Global Market Intelligence. Standard template. Financial Sources.